The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer.
Chi3l1
NETosis
T cell stromal restriction
TNBC
breast cancer
immune microenvironment
immunotherapy
mouse models
neutrophils
Journal
Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918
Informations de publication
Date de publication:
12 Dec 2023
12 Dec 2023
Historique:
received:
23
03
2023
revised:
22
09
2023
accepted:
05
11
2023
pubmed:
2
12
2023
medline:
2
12
2023
entrez:
1
12
2023
Statut:
ppublish
Résumé
In triple-negative breast cancer (TNBC), stromal restriction of CD8
Identifiants
pubmed: 38039967
pii: S1074-7613(23)00483-1
doi: 10.1016/j.immuni.2023.11.002
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2755-2772.e8Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests J.A.E. is a co-founder of Elkurt Therapeutics and is a founder of and stockholder in and serves on the Scientific Advisory Board for Ocean Biomedical Inc., which develops inhibitors of 18-glycosyl hydrolases as therapeutics. C.G.L. and S.K. are consultants for Ocean Biomedical Inc. J.A.E., C.G.L., and S.K. have a patent entitled “methods and composition relating to anti-CHI3L1 antibody reagents” (US Patent 10253111).